The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.
 
Saranya Chumsri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; bioTheranostics; Eisai; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Puma Biotechnology; Syndax
Research Funding - Array BioPharma; Merck
 
Zhuo Li
No Relationships to Disclose
 
Tracy Shachner
No Relationships to Disclose
 
Pooja Advani
No Relationships to Disclose
 
Kostandinos Sideras
No Relationships to Disclose
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Gerardo Colon-Otero
Research Funding - Novartis (Inst)
 
Keith L. Knutson
Research Funding - MacroGenics
Patents, Royalties, Other Intellectual Property - Marker Therapeutics
 
Aziza Nassar
No Relationships to Disclose
 
Edith A. Perez
Employment - Genentech
Stock and Other Ownership Interests - Genentech/Roche
Consulting or Advisory Role - Daiichi Sankyo; Puma Biotechnology; Seagen
 
E Aubrey Thompson
No Relationships to Disclose